MUC1


Also found in: Acronyms.

MUC1

A 265- to 400-kD transmembrane glycoprotein encoded by MUC1 on chromosome 1q21, which is found in milk-fat globule membranes.

Normal expression
Normal epithelia and perineurial cells, choroid plexus, arachnoid granulation, epithelioid histiocytes.

Abnormal expression
Neoplastic epithelia, meningiomas, mesotheliomas, mesenchymal tumours, some lymphomas, anaplastic large cell lymphomas.
References in periodicals archive ?
The tumour-associated MUC1 protein is adorned with a distinctive, shorter, set of carbohydrates that set it apart from healthy cells.
She explains that when cancer occurs, the architecture of the cell changes and MUC1 is produced at high levels, promoting tumor formation.
On the other hand, pancreatobiliary phenotype with MUC1 expression appears to be more common in the West.
TG4010 is an immunotherapy that has been designed to express the coding sequences of the MUC1 tumor-associated antigen and the cytokine, Interleukin-2.
CV301 is designed to generate a T-cell response to both CEA and MUC1 - two tumour antigens that are highly present in bladder cancers.
14,17,19,24,28) Some have used the mucin-associated glycoprotein (MUC) immunoprofile to determine the phenotype of the AC, because intestinal-type ACs express MUC2, whereas biliary carcinomas coexpress MUC1 and MUC5AC (but not MUC2).
Briefly, epithelial cell adhesion molecule (EPCAM; also known as GA733-2)-positive and mucin 1, cell surface associated (MUC1)-positive cells were targeted, followed by RNA isolation and subsequent gene expression analysis by reversetranscription (RT) and multiplex PCR, detecting the tumor-associated transcripts EPCAM, MUC1, and mucin 16, cell surface associated (MUC16; also known as CA125) (AdnaTest OvarianCancerDetect; AdnaGen AG).
Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomized Phase III START trial of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Patients whose circulating tumour cells expressed the MUC1 protein, which has been associated with more aggressive pancreatic cancer, trended towards a shorter median overall survival than those whose circulating tumour cells did not express the protein, at 85.
These include OvaRex MAb for tumors expressing the CA 125 antigen, BrevaRex MAb for tumors expressing the MUC1 antigen, GivaRex MAb for tumors expressing the CA 19.
AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer.
The partnership will evaluate each firm's vaccine platform, separately and in combination, with the aim of developing a tumour MUC1 vaccine that can produce a broad range of anti-tumour antibody and T cell responses.